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the ﬁrst 12-month observational period. Out of 505 total sub-
jects enrolled at (12 months) follow-up, 467 patients fully com-
pleted ICIQ-LF. The average variation observed in patients’
reported overall “impact of symptoms” was -1.92 (SD 3.36;
range -7; 10), suggesting a reported improvement in QoL from
baseline. The frequency of women who complained of urine
leakage shows a signiﬁcant decrease from baseline to follow up
(68% Vs 55.6%). Consistently, the number of patients com-
plaining of limited activities due to urinary leakage decreased
from 56.5% to 42%. The W-IPSS was compiled by 83% of all
subjects. For all symptoms considered, greater improvement in
QoL was observed were symptoms showed higher remission
rates and lower persistency and incidence rates. An overall
improvement was conﬁrmed also by SF-36. RESULTS: 49.2%
of patients at follow-up reported a good health status (to various
degrees) versus 10.7% at baseline. CONCLUSION: According
to ICIQ-LF and W-IPSS an overall condition improvement was
registered at 12 months from baseline with respect to all LUT
symptoms (storage, voiding and post-micturition categories). A
correlation between increased QoL and observed symptoms
remission rates was detected by all questionnaires.
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OBJECTIVE: Hemophilia treatment has prolonged patients’ life
expectancy and is now focused on improving their Health-
Related Quality-of-Life (HRQoL). We evaluated HRQoL of
adult hemophilic patients without inhibitors. METHODS: The
Cost Of Care of HEmophilia (COCHE) study is a naturalistic,
multicenter, longitudinal study. Patients without inhibitors aged
>18 years were sequentially enrolled at 23 Italian Hemophilia
Care Centers. Information collected was on: socio-demograph-
ics, clinical, resource absorption (direct, indirect costs), HRQoL
(intangible costs) and treatment satisfaction. The following
results pertain to the HRQoL evaluated with two generic instru-
ments: EuroQol (EQ-5D) and Short Form-36 (SF-36). RESULTS:
232 patients were enrolled (median age = 34.3, ranging from 18
to 74), 86.6% with hemophilia A, 72.4% severely affected. At
the time of enrolment 81.0% of patients had chronic hepatic C,
25.0% hepatitis B, 15.9% HIV infection. Most of the patients
(87.8%) reported some orthopedic problems. Target joints were
present in 57.0% of patients. Bleeding occurred on average 2.10
times per patient/month (median 1.44, ranging from 0 to 26).
EQ-5D proﬁle showed that 77.9% of patients complained of
moderate or extreme “pain/discomfort”, 63.5% had problems
with “mobility”, 48.9% were anxious or depressed, 40% had
problems in doing “usual activities”, 12.2% problems with “self-
care”. EQ-Visual Analogue Scale had a mean value of 66.2
(median 70.0, ranging from 9 to 100). The mean+/-SD utility
score was 0.7+/-0.2 (median 0.7, ranging from -0.2 to 1). These
results were conﬁrmed by the SF-36: in particular, the mean+/-
SD Physical Component Summary score was 36.9+/-10.7
(median 35.2, from 15.2 to 55.0); the mean+/-SD Mental Com-
ponent Summary score was 50.2+/-11.8, (median 52.8, from
15.5 to 68.1). CONCLUSION: Hemophilic patients without
inhibitors showed impaired levels of general HRQoL. In partic-
ular the physical component of HRQoL was sensitively com-
promised; by contrast the mental component was relatively good
in comparison to the general Italian male population.
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OBJECTIVES: This study assessed the economic value of using
SPECT-DaTSCAN (123I-FP-CIT) in comparison with current
clinical judgment, in the diagnosis of patients with clinically
uncertain Parkinsonism in Italy. METHODS: A cost-effective-
ness analysis was based on a Markov model, comparing a cohort
of patients following a diagnostic pathway including or exclud-
ing DaTSCAN, using a time horizon of 5 years. The model was
populated with direct medical costs (drugs, tests, exams, hospi-
tal admissions, management of adverse events) associated with
diagnosis and treatment, diagnostic accuracy (sensitivity: 97%,
speciﬁcity: 100%), the underlying prevalence of diseases in the
tested population (estimated to be 49%), rates of adverse events,
therapy progression and death. Effectiveness was expressed as
the (gain in) number of years of appropriate therapy per patient.
Model input values were estimated using a double round Delphi
panel performed with 12 Italian specialists. Diagnostic accuracy,
adverse event rates and mortality rates were based on published
studies. RESULTS: The current diagnostic pathway produced on
average 2.3 “adequately treated years” (ATYs) per patient at an
estimated cost of €8893 to the health care system over 5 years.
The DaTSCAN pathway generated on average 4.1 ATYs per
patient at an estimated cost of €8410. Use of DaTSCAN rather
than current diagnostic practice generated an additional 1.8
ATYs at a cost saving of €482 per patient over 5 years. Dis-
counting at 5%, the cost saving became €372 per patient over 5
years. If the use of DaTSCAN decreased other diagnostic work-
up costs by €450 (estimated by clinical expert), cost savings
became €932 (undiscounted) per patient tested. The result is sen-
sitive to the proportion of patients tested. CONCLUSION: The
analysis suggests that using DaTSCAN in patients with clinically
uncertain Parkinsonism is an economically attractive interven-
tion. Greater amounts of time on appropriate therapy are
achieved at less cost to the health care system.
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OBJECTIVES: Self monitoring of blood glucose (SMBG) has
been shown to improve glycemic control of type 2 diabetes in
previous studies (HbA1c improved by 0.3–0.6% with SMBG
versus no SMBG, depending on treatment received) However, the
cost of testing supplies is high and cost-effectiveness has not been
evaluated. METHODS: A validated model (CORE Diabetes
model) projected improvements in lifetime quality-adjusted life
years (QALY), long-term costs, and cost-effectiveness of SMBG
versus no SMBG. Markov/Monte Carlo modeling simulated pro-
gression of complications (cardiovascular, neuropathy, renal and
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eye disease). Transition probabilities and HbA1c-dependent
adjustments came from UKPDS and other major studies. Costs
of complications came from published sources. Direct costs of
diabetes complications and SMBG were projected over patients’
lifetimes from a UK National Health Service perspective. Out-
comes were discounted at 3.5% annually. Sensitivity analysis was
performed. RESULTS: Depending on the type of diabetes treat-
ment (diet and exercise/oral medications/insulin), improvements
in glycemic control with SMBG improved discounted QALYs 
by 0.12 ± 0.14 to 0.21 ± 0.14, with increased total costs of 
£603 ± 909 to £2240 ± 1124/patient, giving incremental cost-
effectiveness ratios of £4853 to £10,670/QALY gained, well
within current UK willingness-to-pay limits. At a threshold of
£30,000/QALY gained, there was a 78–85% probability that
SMBG would be considered cost-effective. SMBG was most cost-
effective in the subgroup of patients treated with diet and exer-
cise. CONCLUSIONS: Improvements in glycemic control with
interventions including SMBG improves patient outcomes with
an acceptable cost-effectiveness ratio in the UK setting.
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OBJECTIVES: Economic evaluations of diagnostic technologies
are less well established than for therapeutic technologies. The
objective of this study was to undertake a cost-effectiveness
analysis in German ofﬁce-based centres of diagnostic strategies
with and without DaTSCAN (123I-FP-CIT) SPECT imaging for
patients with clinically uncertain Parkinsonian syndromes (PS)
to distinguish between PS and essential tremor (ET), one of the
conditions most commonly misdiagnosed as Parkinson’s Disease.
We report initial analytic results based on ofﬁce-based expert
opinion. METHODS: A Markov model was developed to simu-
late the progression of a cohort of patients with clinically uncer-
tain PS who are managed in an ofﬁce-based centre based on
clinical judgment alone or receiving DaTSCAN. Health states
were deﬁned in terms of therapy (PS, ET, none) and underlying
conditions (PS, ET). The model estimated time on potentially
beneﬁcial therapy (PBT: e.g. PS therapy for underlying PS) and
patient management costs over 5 years. Model probability inputs
were from published studies and treatment patterns/resource use
from a panel of German neurologists. Unit costs were from ofﬁ-
cial sources. The cost of a DaTSCAN test (agent plus adminis-
tration) was €929. A total of 40–60% cohort members were
assumed to have underlying PS. DaTSCAN sensitivity and speci-
ﬁcity were 95%/100% (institutional read) and 93%/97%
(blinded read). RESULTS: At 50% underlying prevalence and in
the absence of DaTSCAN, 25% of cohort members had PBT at
the outset, rising to 60% at 6 months and 62% at 5 years. Using
DaTSCAN, 99% of patients had PBT at the outset reducing to
79% at 5 years. DaTSCAN use generated an incremental 1.4 PB
years per patient, and 5-year costs were €795 lower for the
DaTSCAN group. CONCLUSION: Adding non-invasive
imaging to the management of patients with clinically uncertain
PS may be considered to be a cost-saving strategy with an
increase in time on potentially beneﬁcial therapy.
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OBJECTIVES: Cost-consequence analysis of a RP (remifentanil
+ propofol) regimen versus a conventional, commonly used MF
(midazolam + fentanyl) regimen for sedation of mechanically
ventilated postoperative cardiac surgery patients. METHODS:
We conducted a prospective, single-blinded, randomised cost-
consequence study with 80 patients in one German intensive care
unit (ICU). The RP group received remifentanil (6- max. 60mg
kg-1 h-1) and—if sedation at maximal remifentanil dose was
insufﬁcient—propofol (0.5–4.0mg kg-1 h-1). The MF group
received midazolam (0.02–0.2mgkg-1 h-1) and fentanyl (1.0–
7.0mgkg-1 h-1). Direct costs for drugs, material (variable costs
only), and staff were considered (hospital’s perspective, 2003
prices). Sensitivity and scenario analyses were performed with a
decision-analytic model. As the remifentanil dose in the study RP
regimen (baseline) was higher than in routine practice we simu-
lated a “routine practice” scenario: We lowered the mean
remifentanil infusion rate from 41.2mgkg-1 h-1 to 9mgkg-1 h-1,
increased the propofol infusion rate from 2.2mgkg-1 h-1 to 4mg
kg-1 h-1 and assumed that this scenario would have rendered the
same reduction (24%) in staff costs compared to MF regimen
and identical material and drug utilisation (except RP) as at base-
line. RESULTS: Compared to MF regimen, RP regimen (base-
line) led to a signiﬁcantly shorter mechanical ventilation time
(3.5h) and earlier discharge from ICU (18.3h) and equal average
net costs of €1700 for the ICU stay per patient. The routine prac-
tice scenario rendered 53% lower RP medication costs than base-
line thus yielding net savings of €200 per patient. These results
are sensitive to staff and drug cost variations. CONCLUSIONS:
Analysis indicates that RP regimen dominates MF regimen in the
investigated setting as it reduces the mechanical ventilation time
and hence the risk of ventilator-associated morbidity at equal
costs (baseline) or even savings (scenario).
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OBJECTIVE: To assess the usefulness of daily practice diagnos-
tic methods (medical history, I-PSS questionnaire, digital rectal
examination (DRE) and prostate-speciﬁc antigen (PSA)) for the
diagnosis of Benign Prostatic Hyperplasia (BPH). METHODS:
A total of 363 consecutive patients with suspected BPH seen at
urological outpatient clinics, between April and November 2003,
participated in the study. The following steps were sequentially
followed to deﬁne the Initial Diagnosis: 1) medical history; 2) I-
PSS questionnaire; 3) DRE; and 4) PSA. It was then compared
to the Final Diagnosis (gold-standard) after step 5) urinary sed-
iment, residual volume and prostate size by ultrasonography, and
